{"classes":[{"categories":[{"measurements":[{"comment":"DoR cannot be calculated due to none achieved PR or CR.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"4.0"},{"comment":"DoR cannot be calculated due to none achieved PR or CR.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"5.5","value":"5.5"},{"comment":"DoR cannot be calculated due to none achieved PR or CR.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG005","lowerLimit":"3.2","upperLimit":"NA","value":"NA"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG006","lowerLimit":"3.2","upperLimit":"NA","value":"4.2"},{"groupId":"OG007","lowerLimit":"2.8","upperLimit":"23.4","value":"6.3"},{"groupId":"OG008","lowerLimit":"3.0","upperLimit":"5.6","value":"4.3"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG009","lowerLimit":"5.6","upperLimit":"NA","value":"9.8"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG011","lowerLimit":"NA","upperLimit":"NA","value":"19.3"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG012","lowerLimit":"NA","upperLimit":"NA","value":"5.6"}]}],"title":"Median duration of response(month)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"9.6","value":"3.1"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"22.5","value":"1.9"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG002","lowerLimit":"1.7","upperLimit":"NA","value":"12.5"},{"groupId":"OG003","lowerLimit":"1.2","upperLimit":"7.4","value":"3.3"},{"groupId":"OG004","lowerLimit":"1.0","upperLimit":"6.0","value":"4.6"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG005","lowerLimit":"1.2","upperLimit":"NA","value":"4.9"},{"groupId":"OG006","lowerLimit":"4.0","upperLimit":"12.7","value":"5.5"},{"groupId":"OG007","lowerLimit":"2.4","upperLimit":"9.0","value":"4.2"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG008","lowerLimit":"1.4","upperLimit":"NA","value":"4.2"},{"groupId":"OG009","lowerLimit":"5.5","upperLimit":"12.5","value":"10.8"},{"groupId":"OG011","lowerLimit":"1.4","upperLimit":"21.3","value":"3.3"},{"comment":"NA means \"not estimable\" due to the data not being mature (i.e., the number of observed events is lower than 50%).","groupId":"OG012","lowerLimit":"3.2","upperLimit":"NA","value":"5.3"}]}],"title":"Median progression free survival(month)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"7"}],"units":"Participants"}],"description":"To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator.\n\nDoR was presented for patients with confirmed objective response (CR or PR). DoR was the time from date of first documentation of CR or PR, which was subsequently confirmed, to date of first documentation of objective progression or death. Patients who had no documentation of objective progression or death was censored.\n\nPFS was the time from first dose date of sunvozertinib to date of first documentation of progression or death due to any cause, whichever occurred first. Patient who had no PFS event was censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 50 mg once daily continuously.","id":"OG000","title":"Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 100 mg once daily continuously.","id":"OG001","title":"Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 200 mg once daily continuously.","id":"OG002","title":"Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 300 mg once daily continuously.","id":"OG003","title":"Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 400 mg once daily continuously.","id":"OG004","title":"Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.","id":"OG005","title":"Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.","id":"OG006","title":"Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.","id":"OG007","title":"Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"OG008","title":"Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"OG009","title":"Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment.\n\nNo patient was enrolled into this cohort.","id":"OG010","title":"Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"OG011","title":"Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"OG012","title":"Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal"}],"paramType":"MEDIAN","populationDescription":"Only participants in Part A were presented here, while Part B were presented separately. Participants in Part A with baseline and at least one post-treatment tumor assessment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"The maximum median of DoR was 19.3 months, and the maximum median of PFS was 12.5 months for part A.","title":"Part A: DoR and PFS by Investigator.","type":"SECONDARY","unitOfMeasure":"month"}